Abstracts Archive - Page 1380 of 2607 - ACR Meeting Abstracts

Abstract Number: 2907 • 2018 ACR/ARHP Annual Meeting
Comparison of the Joints Ultrasonography in the Patients with Rheumatoid Arthritis Treated By Biological Agents and the Corresponding Synovial Histological Findings
Asami Abe¹, Hajime Ishikawa² and Kunihiko Wakaki³, ¹Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ²Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ³Pathology, Niigata Prefectural Shibata Hospital, Shibata, Japan
Comparison of the joints ultrasonography in the patients with rheumatoid arthritis treated by biological agents and the corresponding synovial histological findings Background/Purpose: In the treatment…
Abstract Number: 2908 • 2018 ACR/ARHP Annual Meeting
Agreement between Ultrasound and Whole Body Magnetic Resonance Imaging Assessment of Joint Inflammation and Enthesitis in Rheumatoid Arthritis Patients
Sin Ngai Ng¹, Mette Bjørndal Axelsen², Mikkel Østergaard³, Iris Eshed⁴, Merete Lund Hetland², Jakob M. Møller⁵, Susanne J Pedersen^6,7 and Lene Terslev⁸, ¹Medicine, Queen Elizabeth Hospital , Hong Kong, Hong Kong, Hong Kong, ²Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ³Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ⁴Department of Radiology, Sheba Medical Center, Israel, Tel Hashomer, Israel, ⁵Dept. of Radiology, Copenhagen University Hospitals, Herlev and Gentofte, Copenhagen, Denmark, ⁶Depart of Rheumatology VRR, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Denmark, ⁷Dept. of Rheumatology, Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ⁸Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark
Background/Purpose: To evaluate the agreement between ultrasound (US), whole body magnetic resonance imaging (WBMRI) and clinical assessment of joint inflammation and enthesitis in rheumatoid arthritis…
Abstract Number: 2909 • 2018 ACR/ARHP Annual Meeting
Diagnostic and Prognostic Value of Ultrasound Compared with Plain Radiography in Knee Osteoarthritis
Annie Yang¹, Fernando Bomfim², Kristen Lee², Mukundan Attur³, Steven B. Abramson⁴ and Jonathan Samuels⁵, ¹Department of Medicine, NYU Langone Health, New York, NY, ²NYU Langone Health, New York, NY, ³Rheumatology, NYU Langone Health, New York, NY, ⁴Dept of Medicine, NYU Langone Health, New York, NY, ⁵Department of Medicine, Divison of Rheumatology, NYU Langone Health, New York, NY
Background/Purpose: Plain radiography of knee osteoarthritis (OA) has inherent diagnostic and prognostic limitations, especially in early disease. Ultrasound (US) examination sheds light on disease activity…
Abstract Number: 2910 • 2018 ACR/ARHP Annual Meeting
Development of a Rheumatoid Arthritis Global Outcome Measure to Enable Comparisons of Patient Experiences across Treatment Arms in Randomized Clinical Trials
Liana Fraenkel¹, W. Benjamin Nowell², Carole Wiedmeyer², Zhenglin Wei³, Kaleb Michaud⁴, Tuhina Neogi⁵, Christine Ramsey¹ and David Broniatowski³, ¹Yale University School of Medicine, New Haven, CT, ²Global Healthy Living Foundation, Upper Nyack, NY, ³George Washington University, Washington, DC, ⁴Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Randomized controlled trials currently report benefits and adverse events (AEs) separately, and therefore do not permit comparisons of patients’ overall experiences on one treatment…
Abstract Number: 2911 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Outcomes Measurement Information System (PROMIS®) Global Health Short Form Is Responsive to Patient Reported Changes in SLE Health Status
Shanthini Kasturi¹, Jackie Szymonifka², Jessica R. Berman³, Kyriakos A. Kirou³, Alana B. Levine³, Lisa R Sammaritano⁴ and Lisa A. Mandl⁴, ¹Medicine/Rheumatology, Tufts Medical Center, Boston, MA, ²Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: The accurate and efficient serial measurement of patient centered outcomes is a priority in the clinical care of SLE. Patient-Reported Outcomes Measurement Information Systems…
Abstract Number: 2912 • 2018 ACR/ARHP Annual Meeting
Lupus Flare Activity from the Patient Perspective
Winnie Nelson¹, Patricia Katz², R. Paola Daly³, Lauren Topf³, Erin Connolly-Strong⁴ and Michael Reed⁵, ¹Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Bedminster, NJ, ²University of California San Francisco, San Francisco, CA, ³Lupus Foundation of America, Washington, DC, ⁴Mallinckrodt ARD, Inc., Bedminster, NJ, ⁵Vedanta Research, Chapel Hill, NC
Background/Purpose: Lupus patients may experience flares in disease activity that require rapid management. This study describes the experience, identification, and management of a flare from…
Abstract Number: 2913 • 2018 ACR/ARHP Annual Meeting
A Draft Modified Core Domain Set for Patient-Reported Outcomes (PRO) in Patients with Idiopathic Inflammatory Myopathies (IIM): An Omeract Report
Malin Regardt^1,2, Christopher A. Mecoli^3,4,5, Jin Kyun Park^{6,7,8,9,10,11,12,13,14}, Merrilee Needham¹⁵, Ingrid De Groot¹⁶, Catherine Sarver¹⁷, Ingrid E. Lundberg¹⁸, Beverly Shea¹⁹, Marianne De Visser²⁰, Yeong Wook Song¹³, Clifton O. Bingham III²¹, Lisa Christopher-Stine^22,23,24 and Helene Alexanderson²⁵, ¹Learning, Informatics,Management and Ethics, Karolinska institutet, Stockholm, Sweden, ²Function Area Occupational Therapy and Physical Therapy, Karolinska University Hospital, Stockholm, Sweden, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Johns Hopkins University, Baltimore, MD, ⁶Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, Republic of (South), ⁷Division of Rheumatology, Seoul National University Hospital, Seoul, Korea, Republic of (South), ⁸Department of Molecular medicine and biopharmaceutical science, Seoul National University, seoul, Korea, Republic of (South), ⁹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ¹⁰[email protected], Division of Rheumatology, Seoul National University Hospital, Seoul, Korea, Republic of (South), ¹¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ¹²Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, Korea, Republic of (South), ¹³Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South), ¹⁴Department of Molecular Medicine and Biopharmaceutical Sciences, BK21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Korea, Republic of (South), ¹⁵Murdoch University, Perth, Australia, ¹⁶patient research partner, Rotterdam, Netherlands, ¹⁷patient research partner, maryland, MD, ¹⁸Department of Medicine, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden, ¹⁹Bruyere Research Institute, Ottawa, ON, Canada, ²⁰Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands, ²¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²²Ste 4100 Rm 409, Johns Hopkins University School of Medicine, Baltimore, MD, ²³Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ²⁴Medicine and Neurology, Johns Hopkins University, Baltimore, MD, ²⁵Department of NVS, Division of Physical Therapy, Karolinska Institutet, Huddinge, Sweden
A Draft Modified Core Domain Set for Patient-Reported Outcomes (PRO) in Patients with Idiopathic Inflammatory Myopathies (IIM): An OMERACT ReportBackground/Purpose: The OMERACT Myositis special interest…
Abstract Number: 2914 • 2018 ACR/ARHP Annual Meeting
Examination of Psychometric Properties of the Patient-Reported Outcomes Measurement Information System Fatigue 4-Item Short Form in Psoriatic Arthritis
Patricia Katz^1,2, Alexis Ogdie³, Evo Alemao⁴, Jayanti Mukherjee⁴ and Kaleb Michaud^2,5, ¹Forward/National Data Bank for Rheumatic Diseases, Wichita, KS, ²University of California San Francisco, San Francisco, CA, ³Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Bristol-Myers Squibb, Princeton, NJ, ⁵Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: PROMIS (Patient-Reported Outcomes Measurement Information System) measures have not been tested in psoriatic arthritis (PsA). We examined the reliability, validity and responsiveness of the…
Abstract Number: 2915 • 2018 ACR/ARHP Annual Meeting
Can Passively-Collected Phone Behavior Determine Rheumatic Disease Activity?
Kaleb Michaud, Sofia Pedro and Rebecca Schumacher, FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Advances in reality mining combined with the pervasive use of smart phones have shown measurable changes in phone behavior due to changes in health.…
Abstract Number: 2916 • 2018 ACR/ARHP Annual Meeting
New JADAS10- and cJADAS10-Based Cutoffs for Juvenile Idiopathic Arthritis Disease Activity States: Validation in a Multinational Dataset of 4830 Patients
Alessandro Consolaro^1,2, Chiara Trincianti¹, Pieter van Dijkhuizen³, Giedre Januskeviciute⁴, Gabriella Giancane⁵, Alessandra Alongi¹, Joost Swart³, Nicola Ruperto^6,7 and Angelo Ravelli^2,8, ¹University of Genova, Genova, Italy, ²Clinica Pediatrica - Reumatologia, Istituto Giannina Gaslini, Genova, Italy, ³UMC Utrecht, Wilhelmina Children’s Hospital, Utrecht, Netherlands, ⁴Istituto Giannina Gaslini, Genova, Italy, ⁵Clinica Pediatrica - Reumatologia, Istituto Giannina Gaslini, Genoa, Italy, ⁶Universita di Genova Pediatria II, Genova, Italy, ⁷Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ⁸University of Genova, Genoa, Italy
Background/Purpose: The Juvenile Arthritis Disease Activity Score (JADAS) and its clinical version excluding the acute phase reactant (cJADAS) were developed for measuring disease activity in…
Abstract Number: 2917 • 2018 ACR/ARHP Annual Meeting
Multiplex Serum Biomarker Analysis before and during Therapy with Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis
Tanja Hinze¹, Christoph Kessel¹, Claas Hinze¹, Julia Seibert², Hermann Gram² and Dirk Foell³, ¹Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ²Novartis, Basel, Switzerland, ³Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany
Background/Purpose: Canakinumab (CAN), a monoclonal anti-interleukin (IL)-1β antibody, is approved for the treatment of systemic juvenile idiopathic arthritis (SJIA). CAN-treated patients with SJIA showed a…
Abstract Number: 2918 • 2018 ACR/ARHP Annual Meeting
Physical Activity in Canadian Children with Juvenile Idiopathic Arthritis: The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)
Lori Tucker¹, Jaime Guzman¹, Kristin Houghton², Dax G. Rumsey³, Elizabeth Stringer⁴, Shirley M.L. Tse⁵, Rosie Scuccimarri⁶, Claire LeBlanc⁷, Roberta Berard⁸, Bianca Lang⁹, Karen N Watanabe Duffy¹⁰ and Ciarán M. Duffy¹¹, ¹BC Children's Hospital, Vancouver, BC, Canada, ²Rheumatology/Pediatrics, British Columbia Children's Hospital, Vancouver, BC, Canada, ³Stollery Children's Hospital, Edmonton, AB, Canada, ⁴Department of Rheumatology, IWK Health Centre, Halifax, NS, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶Department of Pediatrics, McGill University Health Centre, Montreal, QC, Canada, ⁷Pediatrics, Montreal Children's Hospital, Montreal, QC, Canada, ⁸Pediatrics, Children's Hospital, London Health Sciences Centre, London, ON, Canada, ⁹Pediatrics, IWK Health Centre, Halifax, NS, Canada, ¹⁰Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ¹¹Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Physical activity (PA) is an important component of health, and is essential for optimal growth and development. Children with juvenile idiopathic arthritis (JIA) are…
Abstract Number: 2919 • 2018 ACR/ARHP Annual Meeting
An Epidemic: Severe Lung Disease in Patients with Systemic Juvenile Idiopathic Arthritis, Risk Factors and Predictors
Shima Yasin¹, Christopher Towe^2,3, Ndate Fall⁴, Alexei Grom^3,4 and Grant Schulert^1,5, ¹Rheumatology, Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pulmonology, Division of Pulmonology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Division of Rheumatology, Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵Pediatrics, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: There is growing awareness of severe and often fatal chronic lung disease in patients with systemic juvenile idiopathic arthritis (sJIA). However, clinical features and…
Abstract Number: 2920 • 2018 ACR/ARHP Annual Meeting
Correlations of Type I Interferon Score and Interferon Induced Chemokines CXCL10 and CXCL9 with Cutaneous and Muscular Disease Activity in Juvenile Dermatomyositis
Gian Marco Moneta¹, Ivan Caiello¹, Lucilla Rava'², Silvia Rosina³, Luisa Bracci Laudiero^1,4, Angelo Ravelli^3,5, Fabrizio De Benedetti⁶ and Rebecca Nicolai⁷, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ²Epidemiology Unit, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ³University of Genova, Genova, Italy, ⁴Institute of Translational Pharmacology, CNR, Roma, Italy, ⁵Rheumatology, Giannina Gaslini Institute, Genova, Italy, ⁶IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ⁷Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Background/Purpose: Interferons (IFNs) seem to play an important role in the pathogenesis of juvenile dermatomyositis (JDM). We previously reported that expression of both type I…
Abstract Number: 2921 • 2018 ACR/ARHP Annual Meeting
The Performance of the Newly Proposed EULAR/Acr Classification Criteria in Juvenile-Onset Systemic Lupus Erythematosus
Sezgin Sahin¹, Sule Bektas¹, Amra Adrovic¹, Oya Koker², Kenan Barut¹ and Ozgur Kasapcopur³, ¹Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ²Istanbul University, Istanbul Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey
Background/Purpose: To avoid misclassifications, a new set of classification criteria have been developed by the collaboration of the EULAR/ACR and the draft was presented at…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].